Hyperfine's Clinical Research Using Swoop System For Alzheimer's Disease Monitoring To Be Presented At The 2024 Alzheimer's Association International Conference
Hyperfine's Clinical Research Using Swoop System For Alzheimer's Disease Monitoring To Be Presented At The 2024 Alzheimer's Association International Conference
Portable ultra-low-field MR brain imaging provides affordable and accessible technology that may help physicians monitor ARIA and Alzheimer's disease progression in diverse professional care settings.
便攜式超低場MR腦成像技術提供了經濟實惠和易於獲取的技術，可以幫助醫生在各種專業護理環境中監測ARIA和阿爾茨海默病的進展。
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop system—today announced that two presentations on the clinical utility of portable ultra-low-field MRI for Alzheimer's disease monitoring have been accepted in the developing topics poster sessions at the upcoming 2024 Alzheimer's Association International Conference, July 28–August 1 in Philadelphia.
納斯達克上市公司Hyperfine Inc.(NASDAQ:HYPR)是一家開拓性的醫療技術公司，通過首款獲得FDA認證的便攜式磁共振腦成像系統——Swoop系統，重新定義了腦部成像技術，今日宣佈，兩項關於便攜式超低場MRI在阿爾茨海默病監測方面的臨床應用話題，已被接受並列入即將於2024年7月28日至8月1日在費城舉行的阿爾茨海默病國際大會的發展話題海報展示。
These presentations, submitted by clinicians from Washington University in St. Louis, Massachusetts General Hospital, and Yale University, highlight promising applications of portable ultra-low-field MR imaging within the Alzheimer's care continuum.
這些演示文稿由華盛頓大學、馬薩諸塞州總醫院和耶魯大學的臨床醫生提交，突出了便攜式超低場MRI成像在阿爾茨海默病護理連續中的有前途的應用。